{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:17:19Z","timestamp":1789705039339,"version":"4.0.1"},"reference-count":34,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,11,10]]},"DOI":"10.1253\/circrep.cr-25-0091","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T22:07:42Z","timestamp":1757110062000},"page":"1116-1124","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Exposure to High Low-Density Lipoprotein Cholesterol Levels and Clinical Course in Secondary Prevention After Coronary Artery Disease"],"prefix":"10.1253","volume":"7","author":[{"given":"Ichiro","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Cardiovascular Center, KKR Takamatsu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagari","family":"Mukaida","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, KKR Takamatsu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensaku","family":"Wada","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, KKR Takamatsu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Kurozumi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, KKR Takamatsu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunetatsu","family":"Namba","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, KKR Takamatsu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Takagi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, KKR Takamatsu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Grundy SM, Stone NJ. 2018 guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. <i>J Am Coll Cardiol<\/i> 2019; 73: 3168\u20133209."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bor\u00e9n J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>Eur Heart J<\/i> 2020; 41: 2313\u20132330.","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Imano H, Noda H, Kitamura A, Sato S, Kiyama M, Sankai T, et al. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: Coronary Risk in Community Study (CIRCS). <i>Prev Med<\/i> 2011; 52: 381\u2013386.","DOI":"10.1016\/j.ypmed.2011.02.019"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Packard C, Chapman MJ, Sibartie M, Laufs U, Masana L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: Opportunities and challenges. <i>Heart<\/i> 2021; 107: 1369\u20131375.","DOI":"10.1136\/heartjnl-2020-318760"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidemia: Lipid modification to reduce cardiovascular risk. <i>Eur Heart J<\/i> 2020; 41: 111\u2013188.","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): A randomized superiority trial. <i>Circulation<\/i> 2018; 137: 1997\u20132009.","DOI":"10.1161\/CIRCULATIONAHA.117.032615"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kurobe M, Baba K, Nunohiro T, Ishizaki M, Furudono S, Nakata T, et al. Impact of implementation of a region-wide low-density lipoprotein cholesterol management clinical pathway for the secondary prevention of acute myocardial infarction. <i>Circ J<\/i> 2024; 88: 1825\u20131832.","DOI":"10.1253\/circj.CJ-24-0338"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yoshikawa M, Honda A, Arashi H, Shibahashi E, Otsuki H, Kawada-Watanabe E, et al. Addition of ezetimibe to intensive lipid-lowering therapy is associated with a lower incidence of heart failure in patients with acute coronary syndrome. <i>Circ J<\/i> 2024; 88: 1819\u20131824.","DOI":"10.1253\/circj.CJ-24-0536"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. <i>J Atheroscler Thromb<\/i> 2024; 31: 641\u2013853.","DOI":"10.5551\/jat.GL2022"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC Jr, Dai D, et al. Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in the Get With the Guidelines. <i>Am Heart J<\/i> 2009; 157: 111\u2013117.","DOI":"10.1016\/j.ahj.2008.08.010"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Reith C, Armitage J. Management of residual risk after statin therapy. <i>Atherosclerosis<\/i> 2016; 245: 161\u2013170.","DOI":"10.1016\/j.atherosclerosis.2015.12.018"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Perrone V, Sangiorgi D, Buda S, Esposti LD. Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: A retrospective study. <i>Clinicoecon Outcomes Res<\/i> 2016; 8: 649\u2013655.","DOI":"10.2147\/CEOR.S107992"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M. Cardiovascular risk in post-myocardial infarction patients: Nationwide real-world data demonstrate the importance of a long-term perspective. <i>Eur Heart J<\/i> 2015; 36: 1163\u20131170.","DOI":"10.1093\/eurheartj\/ehu505"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Brown MS, Goldstein JL. Lowering LDL: Not only how low, but also how long? <i>Science<\/i> 2006; 311: 1721\u20131723.","DOI":"10.1126\/science.1125884"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. <i>J Am Coll Cardiol<\/i> 2018; 72: 1141\u20131156.","DOI":"10.1016\/j.jacc.2018.06.046"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Domanski MJ, Tian X, Wu CO, Reis JP, Dey AK, Gu Y, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. <i>J Am Coll Cardiol<\/i> 2020; 76: 1507\u20131516.","DOI":"10.1016\/j.jacc.2020.07.059"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Duncan MS, Vasan RS, Xanthakis V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: Observations from the Framingham Study over 35 years. <i>J Am Heart Assoc<\/i> 2019; 8: e011433.","DOI":"10.1161\/JAHA.118.011433"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular diseases. 1. Evidence from genetic, epidemiological, and clinical studies. Consensus statement from the European Atherosclerosis Society Consensus Panel. <i>Eur Heart J<\/i> 2017; 38: 2459\u20132472.","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on coronary disease progression. <i>N Eng J Med<\/i> 2011; 365: 2078\u20132087.","DOI":"10.1056\/NEJMoa1110874"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nordestgaard BG, Chapman MJ, Hegele RA, Raal FJ, Defesche JC, Wiegman A, et al. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. <i>Eur Heart J<\/i> 2013; 34: 3478\u20133490.","DOI":"10.1093\/eurheartj\/eht273"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive vs. moderate lipid lowering with statins after acute coronary syndromes. <i>N Engl J Med<\/i> 2004; 350: 1495\u20131504.","DOI":"10.1056\/NEJMoa040583"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. White HD. Value of expert opinion in recommending early intensive lipid-lowering in patients with ACS. <i>Eur Heart J Acute Cardiovasc Care<\/i> 2022; 11: 936\u2013938.","DOI":"10.1093\/ehjacc\/zuac136"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early intensive statin therapy on acute coronary syndrome: A meta-analysis of randomized controlled trials. <i>Arch Intern Med<\/i> 2006; 166: 1814\u20131821.","DOI":"10.1001\/archinte.166.17.1814"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sabatine MS, Giugliano RP, Keech AC, Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. <i>N Engl J Med<\/i> 2017; 376: 1713\u20131722.","DOI":"10.1056\/NEJMoa1615664"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes in patients with acute coronary syndrome. <i>N Engl J Med<\/i> 2018; 379: 2097\u20132107.","DOI":"10.1056\/NEJMoa1801174"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nambi V, Bhatt DL. Primary prevention of atherosclerosis: Time taken to take a sel\ufb01e? <i>J Am Coll Cardiol<\/i> 2017; 70: 2992\u20132994.","DOI":"10.1016\/j.jacc.2017.10.068"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Packard CJ, Weintraub WS, Laufs U. New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory. <i>Vascul Pharmacol<\/i> 2015; 71: 37\u201339.","DOI":"10.1016\/j.vph.2015.03.008"},{"key":"28","unstructured":"28. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics \u2013 2015 update: A report from the American Heart Association. <i>Circulation<\/i> 2015; 131: e29\u2013e322."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Daghlas I, Gill D. Low-density lipoprotein cholesterol and lifespan: A Mendelian randomization study. <i>Br J Clin Pharmacol<\/i> 2021; 87: 3916\u20133924.","DOI":"10.1111\/bcp.14811"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Park SJ, Kang SJ, Ahn JM, Chang M, Yun SC, Roh JH, et al. Effect of statin treatment on modifying plaque composition: A double-blind, randomized study. <i>J Am Coll Cardiol<\/i> 2016; 67: 1772\u20131783.","DOI":"10.1016\/j.jacc.2016.02.014"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, et al. Effect of evolocumab on the progression of coronary disease in statin-treated patients: A GLAGOV randomized clinical trial. <i>JAMA<\/i> 2016; 316: 2373\u20132384.","DOI":"10.1001\/jama.2016.16951"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Matsumoto I, Misaki A, Kurozumi M, Namba T, Takagi Y. Impact of non-fasting triglycerides\/high-density lipoprotein cholesterol ratio on secondary prevention in patients treated with statins. <i>J Cardiol<\/i> 2018; 71: 10\u201315.","DOI":"10.1016\/j.jjcc.2017.07.012"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Matsumoto I, Moriya S, Kurozumi M, Namba T, Takagi Y. Relationship between serum uric acid levels and the incidence of cardiovascular events after percutaneous coronary intervention. <i>J Cardiol<\/i> 2021; 78: 550\u2013557.","DOI":"10.1016\/j.jjcc.2021.08.005"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Idei M, Hirayama S, Miyake N, Kon M, Horiuchi Y, Ueno T, et al. Mean postprandial triglyceride concentration is an independent risk factor for carotid atherosclerosis in patients with type 2 diabetes. <i>Clin Chim Acta<\/i> 2014; 430: 134\u2013139.","DOI":"10.1016\/j.cca.2013.12.022"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/11\/7_CR-25-0091\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:24:24Z","timestamp":1763177064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/11\/7_CR-25-0091\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0091","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"CR-25-0091"}}